ctDNA Dynamics MRD Agent
The ctDNA Dynamics MRD Agent provides comprehensive analysis of circulating tumor DNA dynamics for molecular residual disease (MRD) detection, treatment response monitoring, and early relapse prediction. It integrates tumor-informed and tumor-naive approaches with temporal modeling for longitudinal ctDNA analysis.
When to Use This Skill
- When monitoring minimal/molecular residual disease post-treatment.
- For tracking treatment response through ctDNA kinetics.
- To predict relapse before clinical/radiological detection.
- When assessing tumor burden dynamics during therapy.
- For early detection of acquired resistance mutations.
Core Capabilities
MRD Detection: Ultra-sensitive detection of residual disease (LOD 0.001% VAF).
Kinetic Modeling: Model ctDNA clearance and doubling time.
Response Prediction: Predict treatment response from early ctDNA dynamics.
Relapse Prediction: Identify molecular relapse months before imaging.
Resistance Monitoring: Track emergence of resistance mutations.
Multi-Timepoint Integration: Analyze longitudinal ctDNA trajectories.
Detection Approaches
| Approach |
Method |
LOD |
Best Use Case |
| Tumor-Informed |
Track known mutations |
0.001% |
Post-surgical MRD |
| Tumor-Naive |
Panel-based detection |
0.1% |
Screening, unknown primary |
| WGS-Based |
Fragmentomics + mutations |
0.01% |
Comprehensive profiling |
| Methylation |
cfDNA methylation |
0.1% |
Tissue of origin, early detection |
Kinetic Parameters
| Parameter |
Definition |
Clinical Meaning |
| ctDNA Half-Life |
Time to 50% reduction |
Treatment sensitivity |
| Doubling Time |
Time to 2x increase |
Tumor growth rate |
| Nadir |
Lowest ctDNA level |
Depth of response |
| Time to Nadir |
Days to reach nadir |
Response kinetics |
| Clearance Rate |
Exponential decay constant |
Treatment efficacy |
| Lead Time |
MRD+ to clinical relapse |
Early detection window |
Workflow
Input: Serial ctDNA measurements (VAF or copies/mL), timepoints, treatment dates.
QC: Assess sequencing quality, coverage, tumor fraction.
Mutation Tracking: Quantify tracked variants across timepoints.
Kinetic Modeling: Fit exponential/sigmoidal models to dynamics.
MRD Calling: Determine MRD status with confidence intervals.
Resistance Detection: Identify emerging resistant clones.
Output: MRD status, kinetic parameters, predictions, visualizations.
Example Usage
User: "Analyze this patient's serial ctDNA data to assess MRD status and predict relapse risk."
Agent Action:
python3 Skills/Oncology/ctDNA_Dynamics_MRD_Agent/ctdna_mrd_analysis.py \
--ctdna_data serial_ctdna.tsv \
--tracked_mutations tumor_mutations.vcf \
--sample_times 0,14,42,90,180 \
--treatment_start 0 \
--surgery_date 7 \
--cancer_type colorectal \
--output mrd_analysis/
Input Data Format
Sample_ID Timepoint_Days Mutation VAF Copies_per_mL Coverage
PT001_T0 0 TP53_R248Q 5.2 1500 15000
PT001_T1 14 TP53_R248Q 2.1 620 18000
PT001_T2 42 TP53_R248Q 0.05 15 20000
PT001_T3 90 TP53_R248Q 0.002 0.6 22000
Output Components
| Output |
Description |
Format |
| MRD Status |
Positive/Negative at each timepoint |
.csv |
| Kinetic Parameters |
Half-life, doubling time, nadir |
.json |
| Response Classification |
Major/Minor/No response |
.csv |
| Relapse Risk |
Probability and predicted time |
.json |
| Dynamics Plot |
ctDNA trajectory visualization |
.png, .pdf |
| Resistance Variants |
Emerging mutations |
.vcf |
| Clonal Evolution |
Clone frequency over time |
.csv |
Response Definitions
| Response Category |
ctDNA Change |
Clinical Correlation |
| Major Molecular Response |
>2 log reduction |
Excellent prognosis |
| Molecular Response |
1-2 log reduction |
Good prognosis |
| Stable Molecular Disease |
<1 log change |
Intermediate |
| Molecular Progression |
>0.5 log increase |
Poor prognosis |
Cancer-Specific Parameters
| Cancer Type |
Typical Half-Life |
MRD Lead Time |
ctDNA Shedding |
| Colorectal |
1-2 days |
6-12 months |
High |
| Lung (NSCLC) |
1-3 days |
3-6 months |
High |
| Breast |
2-5 days |
6-18 months |
Moderate |
| Pancreatic |
1-2 days |
3-6 months |
High |
| Melanoma |
2-4 days |
3-9 months |
Variable |
AI/ML Components
Kinetic Modeling:
- Non-linear mixed effects models
- Bayesian hierarchical models
- Gaussian process regression
MRD Detection:
- Error-suppressed variant calling
- Machine learning noise filtering
- Duplex UMI deduplication
Relapse Prediction:
- Time-series forecasting (LSTM, Transformers)
- Survival analysis (Cox, Random Survival Forests)
- Multi-mutation integration
Clinical Trial Support
| Application |
Endpoint |
ctDNA Metric |
| Neoadjuvant |
pathCR surrogate |
Pre-surgery clearance |
| Adjuvant |
DFS surrogate |
Post-surgery MRD |
| Metastatic |
PFS/OS surrogate |
ctDNA dynamics |
| Maintenance |
Duration decision |
MRD negativity |
Prerequisites
- Python 3.10+
- Variant callers (Mutect2, Strelka)
- UMI-aware pipelines
- scipy, lifelines, survival analysis tools
- PyTorch for deep learning models
Related Skills
- MRD_EDGE_Detection_Agent - Ultra-sensitive MRD detection
- Liquid_Biopsy_Analytics_Agent - Comprehensive liquid biopsy
- Tumor_Heterogeneity_Agent - Clonal evolution tracking
- HRD_Analysis_Agent - Genomic biomarkers
Special Considerations
- Tumor Fraction: Low tumor fraction limits sensitivity
- Pre-Analytical: Plasma processing affects cfDNA quality
- Clonal Hematopoiesis: CHIP variants can confound results
- Panel Design: Ensure sufficient mutation coverage
- Timing: Sample timing relative to treatment critical
FDA-Cleared ctDNA Tests
| Test |
Cancer Types |
Application |
| Guardant360 CDx |
Pan-cancer |
Treatment selection |
| FoundationOne Liquid CDx |
Pan-cancer |
Treatment selection |
| Signatera |
Solid tumors |
MRD monitoring |
| Guardant Reveal |
CRC |
MRD detection |
Author
AI Group - Biomedical AI Platform
1---2name: ctdna-dynamics-mrd-agent-23description: AI-powered circulating tumor DNA dynamics analysis for molecular residual disease detection, treatment response monitoring, and early relapse prediction using liquid biopsy.4license: MIT5---67# ctDNA Dynamics MRD Agent89The **ctDNA Dynamics MRD Agent** provides comprehensive analysis of circulating tumor DNA dynamics for molecular residual disease (MRD) detection, treatment response monitoring, and early relapse prediction. It integrates tumor-informed and tumor-naive approaches with temporal modeling for longitudinal ctDNA analysis.1011## When to Use This Skill1213* When monitoring minimal/molecular residual disease post-treatment.14* For tracking treatment response through ctDNA kinetics.15* To predict relapse before clinical/radiological detection.16* When assessing tumor burden dynamics during therapy.17* For early detection of acquired resistance mutations.1819## Core Capabilities20211. **MRD Detection**: Ultra-sensitive detection of residual disease (LOD 0.001% VAF).22232. **Kinetic Modeling**: Model ctDNA clearance and doubling time.24253. **Response Prediction**: Predict treatment response from early ctDNA dynamics.26274. **Relapse Prediction**: Identify molecular relapse months before imaging.28295. **Resistance Monitoring**: Track emergence of resistance mutations.30316. **Multi-Timepoint Integration**: Analyze longitudinal ctDNA trajectories.3233## Detection Approaches3435| Approach | Method | LOD | Best Use Case |36|----------|--------|-----|---------------|37| Tumor-Informed | Track known mutations | 0.001% | Post-surgical MRD |38| Tumor-Naive | Panel-based detection | 0.1% | Screening, unknown primary |39| WGS-Based | Fragmentomics + mutations | 0.01% | Comprehensive profiling |40| Methylation | cfDNA methylation | 0.1% | Tissue of origin, early detection |4142## Kinetic Parameters4344| Parameter | Definition | Clinical Meaning |45|-----------|------------|------------------|46| ctDNA Half-Life | Time to 50% reduction | Treatment sensitivity |47| Doubling Time | Time to 2x increase | Tumor growth rate |48| Nadir | Lowest ctDNA level | Depth of response |49| Time to Nadir | Days to reach nadir | Response kinetics |50| Clearance Rate | Exponential decay constant | Treatment efficacy |51| Lead Time | MRD+ to clinical relapse | Early detection window |5253## Workflow54551. **Input**: Serial ctDNA measurements (VAF or copies/mL), timepoints, treatment dates.56572. **QC**: Assess sequencing quality, coverage, tumor fraction.58593. **Mutation Tracking**: Quantify tracked variants across timepoints.60614. **Kinetic Modeling**: Fit exponential/sigmoidal models to dynamics.62635. **MRD Calling**: Determine MRD status with confidence intervals.64656. **Resistance Detection**: Identify emerging resistant clones.66677. **Output**: MRD status, kinetic parameters, predictions, visualizations.6869## Example Usage7071**User**: "Analyze this patient's serial ctDNA data to assess MRD status and predict relapse risk."7273**Agent Action**:74```bash75python3 Skills/Oncology/ctDNA_Dynamics_MRD_Agent/ctdna_mrd_analysis.py \76 --ctdna_data serial_ctdna.tsv \77 --tracked_mutations tumor_mutations.vcf \78 --sample_times 0,14,42,90,180 \79 --treatment_start 0 \80 --surgery_date 7 \81 --cancer_type colorectal \82 --output mrd_analysis/83```8485## Input Data Format8687```tsv88Sample_ID Timepoint_Days Mutation VAF Copies_per_mL Coverage89PT001_T0 0 TP53_R248Q 5.2 1500 1500090PT001_T1 14 TP53_R248Q 2.1 620 1800091PT001_T2 42 TP53_R248Q 0.05 15 2000092PT001_T3 90 TP53_R248Q 0.002 0.6 2200093```9495## Output Components9697| Output | Description | Format |98|--------|-------------|--------|99| MRD Status | Positive/Negative at each timepoint | .csv |100| Kinetic Parameters | Half-life, doubling time, nadir | .json |101| Response Classification | Major/Minor/No response | .csv |102| Relapse Risk | Probability and predicted time | .json |103| Dynamics Plot | ctDNA trajectory visualization | .png, .pdf |104| Resistance Variants | Emerging mutations | .vcf |105| Clonal Evolution | Clone frequency over time | .csv |106107## Response Definitions108109| Response Category | ctDNA Change | Clinical Correlation |110|-------------------|--------------|---------------------|111| Major Molecular Response | >2 log reduction | Excellent prognosis |112| Molecular Response | 1-2 log reduction | Good prognosis |113| Stable Molecular Disease | <1 log change | Intermediate |114| Molecular Progression | >0.5 log increase | Poor prognosis |115116## Cancer-Specific Parameters117118| Cancer Type | Typical Half-Life | MRD Lead Time | ctDNA Shedding |119|-------------|-------------------|---------------|----------------|120| Colorectal | 1-2 days | 6-12 months | High |121| Lung (NSCLC) | 1-3 days | 3-6 months | High |122| Breast | 2-5 days | 6-18 months | Moderate |123| Pancreatic | 1-2 days | 3-6 months | High |124| Melanoma | 2-4 days | 3-9 months | Variable |125126## AI/ML Components127128**Kinetic Modeling**:129- Non-linear mixed effects models130- Bayesian hierarchical models131- Gaussian process regression132133**MRD Detection**:134- Error-suppressed variant calling135- Machine learning noise filtering136- Duplex UMI deduplication137138**Relapse Prediction**:139- Time-series forecasting (LSTM, Transformers)140- Survival analysis (Cox, Random Survival Forests)141- Multi-mutation integration142143## Clinical Trial Support144145| Application | Endpoint | ctDNA Metric |146|-------------|----------|--------------|147| Neoadjuvant | pathCR surrogate | Pre-surgery clearance |148| Adjuvant | DFS surrogate | Post-surgery MRD |149| Metastatic | PFS/OS surrogate | ctDNA dynamics |150| Maintenance | Duration decision | MRD negativity |151152## Prerequisites153154* Python 3.10+155* Variant callers (Mutect2, Strelka)156* UMI-aware pipelines157* scipy, lifelines, survival analysis tools158* PyTorch for deep learning models159160## Related Skills161162* MRD_EDGE_Detection_Agent - Ultra-sensitive MRD detection163* Liquid_Biopsy_Analytics_Agent - Comprehensive liquid biopsy164* Tumor_Heterogeneity_Agent - Clonal evolution tracking165* HRD_Analysis_Agent - Genomic biomarkers166167## Special Considerations1681691. **Tumor Fraction**: Low tumor fraction limits sensitivity1702. **Pre-Analytical**: Plasma processing affects cfDNA quality1713. **Clonal Hematopoiesis**: CHIP variants can confound results1724. **Panel Design**: Ensure sufficient mutation coverage1735. **Timing**: Sample timing relative to treatment critical174175## FDA-Cleared ctDNA Tests176177| Test | Cancer Types | Application |178|------|--------------|-------------|179| Guardant360 CDx | Pan-cancer | Treatment selection |180| FoundationOne Liquid CDx | Pan-cancer | Treatment selection |181| Signatera | Solid tumors | MRD monitoring |182| Guardant Reveal | CRC | MRD detection |183184## Author185186AI Group - Biomedical AI Platform
majiayu000